1
|
Haddad K, Matteau A, Potter B, Mansour S. ANGIOGRAPHIC PREDICTORS OF CTO PCI SUCCESS: HOW TO GUIDE DECISION MAKING BEYOND THE J-CTO SCORE. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
2
|
Haddad K, Irani T, Potter B, Matteau A, Mansour S. EVALUATION OF THE REAL-WORLD PLACE OF THE ICOSAPENT ETHYL (IPE) FOR THE TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA REQUIRING INVASIVE CORONARY ANGIOGRAM. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Mansour M, De Marco C, Potter B, Cyr V, Tournoux F, Romanelli G. PROGNOSTIC VALUE OF EXERCISE RIGHT VENTRICULAR FREE WALL STRAIN IN PATIENTS WITH SICKLE CELL DISEASE. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|
4
|
Shen H, Sestier M, Beaulieu M, Soltani I, Hillani A, Matteau A, Mansour S, Potter B. ELIGIBILITY FOR ASPIRIN PLUS LOW-DOSE RIVAROXABAN AMONG CARDIOLOGY OUTPATIENTS IN AN ACADEMIC TERTIARY CARE CENTER. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Soltani I, Chatta R, Potter B, Matteau A, Juneau D, Mansour S. PROGNOSTIC VALUE OF PET MPI MYOCARDIAL FLOW RESERVE IN CABG PATIENTS. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
6
|
Berbach L, Potter B, Noiseux N. 3-DIMENSIONAL CARDIOGENIC SHOCK SIMULATOR PHASE I: SUCCESSFUL DEVELOPMENT OF A LARGE ANIMAL CARDIOGENIC SHOCK MODEL. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
Shen H, Sestier M, Soltani I, Beaulieu M, Hillani A, Mansour S, Matteau A, Potter B. GASTROPROTECTION IN PATIENTS ON ANTITHROMBOTIC THERAPY: A QUALITY IMPROVEMENT STUDY. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Antonic V, Sajja V, Sousa J, Nguyen K, Alamneh Y, Garry B, Medina-Rojas M, Wilder D, Vuong C, Potter B, Zurawski D, Shearer J, Black C, Demons S, Long J, Tyner S. Evaluation of Blast Overpressure Exposure Effects on Concentration of Antibiotics in Mice. Mil Med 2020; 185:256-262. [PMID: 32074328 DOI: 10.1093/milmed/usz212] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Infection as sequelae to explosion-related injury is an enduring threat to our troops. There are limited data on the effects of blast on antibiotic pharmacokinetics (PK), pharmacodynamics (PD), and efficacy. The observational study presented here is our Institute's first attempt to address this issue by combining our existing interdepartmental blast, infection modeling, and in vivo PK/PD capabilities and was designed to determine the PK effects of blast on the first-line antibiotic, cefazolin, in an in vivo mouse model. METHODS A total of 160 male BALB/c mice were divided to sham and blast (exposed to blast overpressure of 19 psi) in two biological replicates. At 1 hour after blast/sham exposure, the animals received IV injection of cefazolin (328 mg/kg). Animals were euthanized at 3 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, or 10 hours after the injection. Plasma and liver were analyzed for concentration of cefazolin using mass-spectrometry. RESULTS We observed increases in the concentration of cefazolin in the plasma and liver of blast exposed animals at later time points and increase in elimination half-life. CONCLUSION Our results indicate that blast-induced physiologic changes significantly influence cefazolin PK and suggest that efficacy could be affected in the context of the blast; assessment of efficacy and PD effects require further investigation. Metabolic changes resulting from blast may influence other classes of antibiotics and other therapeutics used with these injuries. Therefore, this may have important treatment considerations in other areas of military medicine.
Collapse
Affiliation(s)
- Vlado Antonic
- CCCRP, 722 Doughten Street, Fort Detrick, MD 21702.,Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Venkatasivasaisujith Sajja
- Blast Induced Neurotrauma Branch, Center for Military Psychiatry and Neurosciences, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Jason Sousa
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Ken Nguyen
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Yonas Alamneh
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Brittany Garry
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Maria Medina-Rojas
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Donna Wilder
- Blast Induced Neurotrauma Branch, Center for Military Psychiatry and Neurosciences, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Chau Vuong
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Brittney Potter
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Daniel Zurawski
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Jonathan Shearer
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Chad Black
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Samandra Demons
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Joseph Long
- Blast Induced Neurotrauma Branch, Center for Military Psychiatry and Neurosciences, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| | - Stuart Tyner
- Wound Infections Department, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500
| |
Collapse
|
9
|
Huard K, Potter B, Saada Y, Haddad K, Matteau A, John N, Mansour S, Banon D. PREVALENCE OF H. PYLORI AMONG PATIENTS UNDERGOING CORONARY ANGIOGRAPHY. Can J Cardiol 2020. [DOI: 10.1016/j.cjca.2020.07.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Jamali P, Callichurn K, Simard P, De Marco C, Saada Y, Matteau A, Schampaert E, Mansour S, Hatem R, Potter B. UPFRONT VS BAILOUT STRATEGIES OF GPIIB-IIIA ANTAGONISTS IN THE TREATMENT OF ST-ELEVATION MYOCARDIAL INFARCTION DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN CONTEMPORARY PRACTICE: A DUAL-CENTER ANALYSIS. Can J Cardiol 2020. [DOI: 10.1016/j.cjca.2020.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Kancharla P, Dodean RA, Li Y, Pou S, Pybus B, Melendez V, Read L, Bane CE, Vesely B, Kreishman-Deitrick M, Black C, Li Q, Sciotti RJ, Olmeda R, Luong TL, Gaona H, Potter B, Sousa J, Marcsisin S, Caridha D, Xie L, Vuong C, Zeng Q, Zhang J, Zhang P, Lin H, Butler K, Roncal N, Gaynor-Ohnstad L, Leed SE, Nolan C, Ceja FG, Rasmussen SA, Tumwebaze PK, Rosenthal PJ, Mu J, Bayles BR, Cooper RA, Reynolds KA, Smilkstein MJ, Riscoe MK, Kelly JX. Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. J Med Chem 2020; 63:6179-6202. [PMID: 32390431 PMCID: PMC7354843 DOI: 10.1021/acs.jmedchem.0c00539] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The global impact of malaria remains staggering despite extensive efforts to eradicate the disease. With increasing drug resistance and the absence of a clinically available vaccine, there is an urgent need for novel, affordable, and safe drugs for prevention and treatment of malaria. Previously, we described a novel antimalarial acridone chemotype that is potent against both blood-stage and liver-stage malaria parasites. Here, we describe an optimization process that has produced a second-generation acridone series with significant improvements in efficacy, metabolic stability, pharmacokinetics, and safety profiles. These findings highlight the therapeutic potential of dual-stage targeting acridones as novel drug candidates for further preclinical development.
Collapse
Affiliation(s)
- Papireddy Kancharla
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Rozalia A. Dodean
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Yuexin Li
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Sovitj Pou
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Brandon Pybus
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Victor Melendez
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lisa Read
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Charles E. Bane
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Brian Vesely
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Mara Kreishman-Deitrick
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Chad Black
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Qigui Li
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Richard J. Sciotti
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Raul Olmeda
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Thu-Lan Luong
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Heather Gaona
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Brittney Potter
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Jason Sousa
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Sean Marcsisin
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Diana Caridha
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lisa Xie
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Chau Vuong
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Qiang Zeng
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Jing Zhang
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Ping Zhang
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Hsiuling Lin
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Kirk Butler
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Norma Roncal
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lacy Gaynor-Ohnstad
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Susan E. Leed
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Christina Nolan
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Frida G. Ceja
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | - Stephanie A. Rasmussen
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | | | - Philip J. Rosenthal
- Department of Medicine, University of California, San Francisco, CA 94143, United States
| | - Jianbing Mu
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville MD 20852, USA
| | - Brett R. Bayles
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
- Global Public Health Program, Dominican University of California, San Rafael CA 94901
| | - Roland A. Cooper
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | - Kevin A. Reynolds
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Martin J. Smilkstein
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Michael K. Riscoe
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Jane X. Kelly
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| |
Collapse
|
12
|
Hussein A, Ralph D, Potter B, Abbruzzese B, Hershey R, Repp K, Shakhtra H, Goel M, Palmer M, Kissling A, Hartings C, Blue M, Rosol M. THU0540 A PHASE 2B STUDY OF INTRAVENOUSLY (IV) ADMINISTERED TC 99M TILMANOCEPT TO DETERMINE DIFFERENTIAL UPTAKE, REPRODUCIBILITY OVER TIME AND IMAGE STABILITY IN HEALTHY SUBJECTS AND IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) ON STABLE TREATMENT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:At present, there are no reliable noninvasive means to directly monitor disease activity in RA patients. Activated macrophages are a critical component of the inflammatory etiology of RA due to their role in prolonged RA joint inflammation and destruction through the release of pro-inflammatory cytokines and chemokines. Tc 99m tilmanocept is a radiopharmaceutical imaging agent that binds with high affinity to the macrophage mannose receptor CD206 that resides on activated macrophages. Previous clinical trials demonstrated safety and tolerability of Tc 99m tilmanocept, as well as a determination of optimal clinical dose and timeframe for RA imaging.Objectives:The current phase 2b study aims to evaluate reproducibility and stability of imaging and will assess quantitative Tc 99m tilmanocept uptake cut points that reliably enable discrimination between joints of healthy people and RA patients.Methods:The analysis cohort contained 18 healthy controls (HC) clinically free of inflammatory joint disease and 12 subjects with clinically diagnosed RA who are on stable anti-inflammatory and/or anti-rheumatic therapy. Each subject received a 150-mcg dose of tilmanocept radiolabeled with 10 mCi of Tc 99m in a 3mL IV injection. Injection was followed by planar imaging at 60 and 180 minutes for both HC and RA subjects on study Day 0 and repeated in RA subjects on Day 8. Images were quantitatively assessed to detect localization within synovial spaces of bilateral hands and wrists by determining average pixel intensity in each region of interest relative to average pixel intensity in a joint-specific reference region.Results:Data obtained from the interim analysis support the hypothesis that Tc 99m tilmanocept imaging can provide robust quantitative imaging in HC and RA subjects. Repeat images within and between days demonstrate root mean squared differences that are approximately 10% or less of the observed localization of Tc 99m tilmanocept. Qualitatively, images of HC indicated no disease-related site-specific localization, whereas localization is present in RA subjects at levels expected given the difference in macrophage number and density in different pathotypes of RA. Notably, images from patients with active RA exhibit the same localization patterns on images taken in a test-retest fashion on the same day as well as in subjects with images acquired on Day 0 and Day 8 (see Figure 1). These results show low imaging readout variability, enabling reliable quantification of joints with RA-involved macrophage-mediated inflammation. Analysis of the HC and RA images was used to determine initial quantitative “cut-points” to differentiate between joints with and without the inflammation typically seen in RA.Figure 1.Tilmanocept consistently localizes in areas of macrophage-driven inflammation, demonstrating low variability. RA patients exhibit reproducible localization over a 1-week period. Typical of healthy subjects, no evidence of inflammation-related Tc 99m tilmanocept uptake was observed in the healthy control. Images on the right show same patient imaged on 2 different days.Conclusion:Tc 99m tilmanocept imaging of the joints in healthy subjects as well as in patients with active RA under stable treatment is reproducible and stable over time. The results confirmed that the signal in joints of healthy subjects and RA patients can be quantified and used to establish cut points to distinguish inflamed and non-inflamed joints on a joint-by-joint basis. These results provide the foundation for a noninvasive, objective method to monitor activity in macrophage-driven inflammation in joints of patients with RA.Disclosure of Interests:Ayah Hussein Employee of: Currently employed by Navidea Biopharmaceuticals, David Ralph Consultant of: Previous consultant for Navidea Biopharmaceuticals, Employee of: Currently employed by Navidea Biopharmaceuticals, Beth Potter Employee of: Currently employed by Navidea Biopharmaceuticals, Bonnie Abbruzzese Employee of: Currently employed by Navidea Biopharmaceuticals, Rachael Hershey Employee of: Currently employed by Navidea Biopharmaceuticals, Katherine Repp Employee of: Previously employed by Navidea Biopharmaceuticals, Haya Shakhtra Employee of: Currently employed by Navidea Biopharmaceuticals, Mehak Goel Employee of: Currently employed by Navidea Biopharmaceuticals, Madison Palmer Employee of: Currently employed by Navidea Biopharmaceuticals, Allison Kissling Employee of: Previously employed by Navidea Biopharmaceuticals, Carley Hartings Employee of: Previously employed by Navidea Biopharmaceuticals, Michael Blue Employee of: Currently employed by Navidea Biopharmaceuticals, Michael Rosol Employee of: Currently employed by Navidea Biopharmaceuticals
Collapse
|
13
|
Bui K, Matteau A, Elbarouni B, Bainey K, Fordyce C, Bagai A, Rose B, Lutchmedial S, Leis B, Lavoie A, Cox J, Mansour S, Potter B. MANAGEMENT OF ACUTE CORONARY SYNDROMES BEYOND THE FIRST YEAR: A CANADIAN CLINICAL PRACTICE SURVEY. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
14
|
Dinea D, Matteau A, Mitchell D, Durand M, Mansour S, Le Lorier J, Potter B. COST-EFFECTIVENESS OF SHORTER DURATIONS OF TICAGRELOR-BASED DUAL ANTIPLATELET THERAPY FOLLOWING MYOCARDIAL INFARCTION. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
15
|
Dodean RA, Kancharla P, Li Y, Melendez V, Read L, Bane CE, Vesely B, Kreishman-Deitrick M, Black C, Li Q, Sciotti RJ, Olmeda R, Luong TL, Gaona H, Potter B, Sousa J, Marcsisin S, Caridha D, Xie L, Vuong C, Zeng Q, Zhang J, Zhang P, Lin H, Butler K, Roncal N, Gaynor-Ohnstad L, Leed SE, Nolan C, Huezo SJ, Rasmussen SA, Stephens MT, Tan JC, Cooper RA, Smilkstein MJ, Pou S, Winter RW, Riscoe MK, Kelly JX. Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. J Med Chem 2019; 62:3475-3502. [PMID: 30852885 DOI: 10.1021/acs.jmedchem.8b01961] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Malaria remains one of the deadliest diseases in the world today. Novel chemoprophylactic and chemotherapeutic antimalarials are needed to support the renewed eradication agenda. We have discovered a novel antimalarial acridone chemotype with dual-stage activity against both liver-stage and blood-stage malaria. Several lead compounds generated from structural optimization of a large library of novel acridones exhibit efficacy in the following systems: (1) picomolar inhibition of in vitro Plasmodium falciparum blood-stage growth against multidrug-resistant parasites; (2) curative efficacy after oral administration in an erythrocytic Plasmodium yoelii murine malaria model; (3) prevention of in vitro Plasmodium berghei sporozoite-induced development in human hepatocytes; and (4) protection of in vivo P. berghei sporozoite-induced infection in mice. This study offers the first account of liver-stage antimalarial activity in an acridone chemotype. Details of the design, chemistry, structure-activity relationships, safety, metabolic/pharmacokinetic studies, and mechanistic investigation are presented herein.
Collapse
Affiliation(s)
- Rozalia A Dodean
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States.,Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Papireddy Kancharla
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States
| | - Yuexin Li
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States.,Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Victor Melendez
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Lisa Read
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Charles E Bane
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Brian Vesely
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Mara Kreishman-Deitrick
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Chad Black
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Qigui Li
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Richard J Sciotti
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Raul Olmeda
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Thu-Lan Luong
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Heather Gaona
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Brittney Potter
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Jason Sousa
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Sean Marcsisin
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Diana Caridha
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Lisa Xie
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Chau Vuong
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Qiang Zeng
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Jing Zhang
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Ping Zhang
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Hsiuling Lin
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Kirk Butler
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Norma Roncal
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Lacy Gaynor-Ohnstad
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Susan E Leed
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Christina Nolan
- Division of Experimental Therapeutics , Walter Reed Army Institute of Research , Silver Spring , Maryland 20910 , United States
| | - Stephanie J Huezo
- Department of Natural Sciences and Mathematics , Dominican University of California , San Rafael , California 94901 , United States
| | - Stephanie A Rasmussen
- Department of Natural Sciences and Mathematics , Dominican University of California , San Rafael , California 94901 , United States
| | | | | | - Roland A Cooper
- Department of Natural Sciences and Mathematics , Dominican University of California , San Rafael , California 94901 , United States
| | - Martin J Smilkstein
- Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Sovitj Pou
- Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Rolf W Winter
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States.,Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Michael K Riscoe
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States.,Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| | - Jane X Kelly
- Department of Chemistry , Portland State University , Portland , Oregon 97201 , United States.,Department of Veterans Affairs Medical Center , Portland , Oregon 97239 , United States
| |
Collapse
|
16
|
Zeng Q, Xie L, Zhang J, Vuong C, Potter B, Aylor S, Sousa J, Black C, Li Q. Improving Relative Bioavailability of Oral Imidazolidinedione by Reducing Particle Size Using Homogenization and Ultra-Sonication. Mil Med 2019; 184:106-113. [DOI: 10.1093/milmed/usy368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 11/07/2018] [Accepted: 11/12/2018] [Indexed: 11/14/2022] Open
Abstract
Abstract
Particle size is an important determinant of gastrointestinal absorption of compounds administrated orally. The present study evaluates the effect of a reduction in particle size assessed by homogenization, sonication, and homogenization plus sonication on the bioavailability of imidazolidinedione (IZ), an antimalarial compound with known causal prophylactic activity and radical cure of relapsing malaria. Formulations were administrated intragastrically to mice, and blood samples were collected for LC-MS/MS analysis. The homogenization method manually decreased particle size with minimal variance, resulting in a mean particle diameter of 42.22 μm, whereas the probe sonication method evenly distributed pulses of sound to break apart particles, resulting in a mean diameter of 1.50 μm. Homogenization plus sonication resulted in a mean particle diameter of 1.44 μm, which was similar to that of the sonication method alone. The compound suspensions did not show a significant difference in mean particle size between the different vehicles. The sonically engineered microparticle delivers high sonic energy to the suspension leads to faster breakdown and stabilizing of the micronized particles when compared with homogenizer. The bioavailability of the small particle IZ formulation was 100%, compared to the 55.79% relative bioavailability of IZ with larger particle size. These initial data clearly show that a reduction in particle size of orally administered IZ with probe sonication could significantly increase bioavailability in rodent animals that is affected by a high first-pass effect.
Collapse
Affiliation(s)
- Qiang Zeng
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Lisa Xie
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Jing Zhang
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Chau Vuong
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Brittney Potter
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Samantha Aylor
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Jason Sousa
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Chad Black
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| | - Qigui Li
- Experimental Therapeutics Branch, Walter Reed Army Institute of Research 503 Robert Grant Ave., Silver Spring, MD
| |
Collapse
|
17
|
Boivin-Proulx L, Deneault-Marchand A, Matteau A, Mansour S, Camm J, Fox K, Potter B. UPTAKE OF THE 2016 CCS AF GUIDELINES FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
18
|
Lambert L, Azzi L, Désy F, Potter B, Racine N, Beauchemin J, Noiseux N, Asgar A, Daneault B, de Varennes B, Dumont E, Ibrahim R, Lamarche Y, Martucci G, Palisaitis D, Piazza N, Rodés-Cabau J, Afilalo J, Carrier M, de Guise M, Bogaty P. TRANSCATHETER AORTIC VALVE IMPLANTATION IN QUÉBEC: 4 YEARS OF COMPREHENSIVE EVALUATION AND RELATION TO QUALITY INDICATORS. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
19
|
Marquis-Gravel G, Ieroncig F, Demers S, Ghersi I, Rosca L, Simard P, Massie C, Massicotte G, Lalancette J, Bastiany A, El-Turaby F, Diodati J, Paradis J, Daneault B, L'Allier P.L, Potter B, Jolicoeur M. CONTEMPORARY INCIDENCE OF MURAL THROMBUS FOLLOWING ACUTE ANTERIOR STEMI COMPLICATED BY NEW ANTERO/APICAL WALL MOTION ABNORMALITIES: INSIGHTS FROM THE MULTICENTER MAGIC REGISTRY. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
20
|
El-Turaby F, Matteau A, Mansour S, Potter B. CANADIAN CARDIOLOGIST ATTITUDES REGARDING ANTITHROMBOTIC MANAGEMENT AFTER ANTERIOR STEMI COMPLICATED BY APICAL DYSFUNCTION: RESULTS OF A NATIONWIDE SURVEY. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Lambert L, Azzi L, Asgar A, Potter B, Lamarche Y, deVarennes B, Noiseux N, Carrier M, Daneault B, Généreux P, Martucci G, Racine N, Ibrahim R, Sas G, Bogaty P. EVALUATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN QUÉBEC USING NEWLY-ESTABLISHED CANADIAN CARDIOVASCULAR SOCIETY QUALITY INDICATORS. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
22
|
Tessier L, Brehaut J, Potter B, Chakraborty P, Carroll J, Wilson B. Family History-Taking in Paediatrics: It’s Much More Than Just A Checklist. Paediatr Child Health 2016. [DOI: 10.1093/pch/21.supp5.e63c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND: Family history (FH) is a risk factor for many conditions in pediatric practice; interest has increased in supporting systematic FH taking in this area by identifying core conditions for enquiry and developing point of care tools. There is little published about current practice to inform implementing such changes.
OBJECTIVES: To inform future FH taking interventions by identifying pediatricians' perceptions, attitudes, beliefs, and current practices.
DESIGN/METHODS: The Theoretical Domains Framework (TDF) was used to develop a comprehensive interview scheme. Semi-structured interviews were conducted with community and hospital-based pediatricians Analysis was by the constant comparison method, using a thematic approach. This study was funded by the Canadian Institutes of Health Research.
RESULTS: The data revealed FH taking to be a firmly embedded, but complex aspect of pediatric practice. Participants described FH as part of regular, holistic care, extending to social and interpersonal, as well as clinical purposes; in addition to disease risk assessment, FH information helped clarify diagnosis, and select medication; tailor the overall patient management based on family circumstances; and provide psychosocial support for parents. It was also used as a method to build a relationship with parents/carers. FH and social history information were inextricably linked and often appeared to be the same concept in participants’ minds. Participating pediatricians generally expressed confidence in their FH skills and reported tailoring their approach according to experience, after initial training early in their career. While acknowledging some challenges in ensuring accuracy, they were attuned to nuances in their interactions with parents and children which would affect whether, and what, they were told about illness in the family. Most were not concerned about formal evidence, and would not change their practice except for “good reason”.
CONCLUSION: The use of the TDF helped ensure a comprehensive approach to FH taking in pediatric practice. The findings suggest that FH taking in this setting is a complex activity, embedded in routine care. Recommendations for systematic enquiry about specific conditions cannot be seen as a simple additional activity to current practice. Efforts to make FH taking more systematic may founder if they fail to take into account pediatricians’ attitudes, perspectives, and practices. Further studies should explore and seek to confirm and expand our observations.
Collapse
|
23
|
Jin X, Potter B, Luong TL, Nelson J, Vuong C, Potter C, Xie L, Zhang J, Zhang P, Sousa J, Li Q, Pybus BS, Kreishman-Deitrick M, Hickman M, Smith PL, Paris R, Reichard G, Marcsisin SR. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants. Malar J 2016; 15:280. [PMID: 27188854 PMCID: PMC4869338 DOI: 10.1186/s12936-016-1329-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 05/05/2016] [Indexed: 12/21/2022] Open
Abstract
Background The liver-stage anti-malarial activity of primaquine and other 8-aminoquinoline molecules has been linked to bio-activation through CYP 2D6 metabolism. Factors such as CYP 2D6 poor metabolizer status and/or co-administration of drugs that inhibit/interact with CYP 2D6 could alter the pharmacological properties of primaquine. Methods In the present study, the inhibitory potential of the selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRI) classes of antidepressants for CYP 2D6-mediated primaquine metabolism was assessed using in vitro drug metabolism and in vivo pharmacological assays. Results The SSRI/SNRI classes of drug displayed a range of inhibitory activities on CYP 2D6-mediated metabolism of primaquine in vitro (IC50 1–94 μM). Fluoxetine and paroxetine were the most potent inhibitors (IC50 ~1 µM) of CYP 2D6-mediated primaquine metabolism, while desvenlafaxine was the least potent (IC50 ~94 µM). The most potent CYP 2D6 inhibitor, fluoxetine, was chosen to investigate the potential pharmacological consequences of co-administration with primaquine in vivo. The pharmacokinetics of a CYP 2D6-dependent primaquine metabolite were altered upon co-administration with fluoxetine. Additionally, in a mouse malaria model, co-administration of fluoxetine with primaquine reduced primaquine anti-malarial efficacy. Conclusions These results are the first from controlled pre-clinical experiments that indicate that primaquine pharmacological properties can be modulated upon co-incubation/administration with drugs that are known to interact with CYP 2D6. These results highlight the potential for CYP 2D6-mediated drug–drug interactions with primaquine and indicate that the SSRI/SNRI antidepressants could be used as probe molecules to address the primaquine-CYP 2D6 DDI link in clinical studies. Additionally, CYP 2D6-mediated drug–drug interactions can be considered when examining the possible causes of human primaquine therapy failures. Electronic supplementary material The online version of this article (doi:10.1186/s12936-016-1329-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Xiannu Jin
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Brittney Potter
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Thu-Lan Luong
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Jennifer Nelson
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Chau Vuong
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Corttney Potter
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Lisa Xie
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Jing Zhang
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Ping Zhang
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Jason Sousa
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Qigui Li
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Brandon S Pybus
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Mara Kreishman-Deitrick
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Mark Hickman
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Philip L Smith
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Robert Paris
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Gregory Reichard
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA
| | - Sean R Marcsisin
- Military Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.
| |
Collapse
|
24
|
Weeks A, Li T, Mann P, Gelesko S, Cheng A, Potter B, Bell R, Dierks E, Bui T. Gun shot wounds to the head and neck region among trauma patients – 5-year experience at Legacy Emanuel Medical Center. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Riahi M, Naim C, Gobeil F, Mansour S, Matteau A, Essiambre R, Montigny M, Caron M, Sareault I, Potter B. IMPACT OF A MULTI-PRONGED INTERVENTION ON THE RATE OF INAPPROPRIATE CATHETERIZATION LABORATORY ACTIVATION USING AN AUTOMATED SYSTEM OF PRE-HOSPITAL STEMI DIAGNOSIS. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Naim C, Riahi M, Gobeil F, Matteau A, Mansour S, Essiambre R, Montigny M, Caron M, Sareault I, Potter B. SUSTAINABILITY OF “PHYSICIAN-LESS” AUTOMATED PRE-HOSPITAL STEMI DIAGNOSIS AND CATHETERIZATION LABORATORY ACTIVATION TO ENSURE DOOR-TO-BALLOON TIMES: UPDATE AT 5 YEARS. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
27
|
Metz W, Shuping J, Abbruzzese B, Blue M, Reininger C, Colborn D, Potter B, Cope F. 101. 99mTc-Tilmanocept (TcTm) provides stably localised detection of lymph nodes (LN) in melanoma across all anatomic locations regardless of body mass index (BMI), or day of surgery. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
28
|
Cope F, Metz W, Reininger C, Potter B, Shuping J, Abbruzzese B, Colborn D, Blue M. 104. The false negative rate (FNR) for 99mTc-tilmanocept is crucially low across breast cancer (BC), melanoma (ME), and head/neck squamous cell carcinoma (HNSCC), portending good patient outcome. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
29
|
Mountney A, Shear DA, Potter B, Marcsisin SR, Sousa J, Melendez V, Tortella FC, Lu XCM. Ethosuximide and phenytoin dose-dependently attenuate acute nonconvulsive seizures after traumatic brain injury in rats. J Neurotrauma 2013; 30:1973-82. [PMID: 23822888 DOI: 10.1089/neu.2013.3001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Acute seizures frequently occur following severe traumatic brain injury (TBI) and have been associated with poor patient prognosis. Silent or nonconvulsive seizures (NCS) manifest in the absence of motor convulsion, can only be detected via continuous electroencephalographic (EEG) recordings, and are often unidentified and untreated. Identification of effective anti-epileptic drugs (AED) against post-traumatic NCS remains crucial to improve neurological outcome. Here, we assessed the anti-seizure profile of ethosuximide (ETX, 12.5-187.5 mg/kg) and phenytoin (PHT, 5-30 mg/kg) in a spontaneously occurring NCS model associated with penetrating ballistic-like brain injury (PBBI). Rats were divided between two drug cohorts, PHT or ETX, and randomly assigned to one of four doses or vehicle within each cohort. Following PBBI, NCS were detected by continuous EEG monitoring for 72 h post-injury. Drug efficacy was evaluated on NCS parameters of incidence, frequency, episode duration, total duration, and onset latency. Both PHT and ETX attenuated NCS in a dose-dependent manner. In vehicle-treated animals, 69-73% experienced NCS (averaging 9-10 episodes/rat) with average onset of NCS occurring at 30 h post-injury. Compared with control treatment, the two highest PHT and ETX doses significantly reduced NCS incidence to 13-40%, reduced NCS frequency (1.8-6.2 episodes/rat), and delayed seizure onset: <20% of treated animals exhibited NCS within the first 48 h. NCS durations were also dose-dependently mitigated. For the first time, we demonstrate that ETX and PHT are effective against spontaneously occurring NCS following PBBI, and suggest that these AEDs may be effective at treating post-traumatic NCS.
Collapse
Affiliation(s)
- Andrea Mountney
- 1 Branch of Brain Trauma Neuroprotection and Neurorestoration, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research , Silver Spring, Maryland
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Milner E, Sousa J, Pybus B, Auschwitz J, Caridha D, Gardner S, Grauer K, Harris E, Hickman M, Kozar MP, Lee P, Leed S, Li Q, Melendez V, Moon J, Ngundam F, O'Neil M, Parriott S, Potter B, Sciotti R, Tangteung A, Dow GS. Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur J Drug Metab Pharmacokinet 2013; 37:17-22. [PMID: 22314893 DOI: 10.1007/s13318-012-0080-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 01/12/2012] [Indexed: 10/14/2022]
Abstract
Ketotifen is known to exhibit antimalarial activity in mouse and monkey malaria models. However, the low plasma levels and short half life of the drug do not adequately explain its in vivo efficacy. We synthesized most of the known metabolites of ketotifen and evaluated their antimalarial activity and pharmacokinetics in mice. Norketotifen, the de-methylated metabolite of ketotifen, was a more potent antimalarial in vitro as compared to ketotifen, and exhibited equivalent activity in vivo against asexual blood and developing liver-stage parasites. After ketotifen dosing, norketotifen levels were much higher than ketotifen relative to the IC50s of the compounds against Plasmodium falciparum in vitro. The data support the notion that the antimalarial activity of ketotifen in mice is mediated through norketotifen.
Collapse
Affiliation(s)
- Erin Milner
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Cope F, Metz W, Blue M, Potter B, Christman L, King D. Exploitation Targeting of the CD206 Receptor in Lymph Node-resident Reticuloendothelial Cells With a Novel Synthetic 99m Tc-ligand (Tilmanocept) Significantly Enhances Localization in Contrast to 99m Tc-Colloid: A New Meta-analysis. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Mytton J, Stewart-Brown S, Hewison C, Potter B, Azuike V, Park P. The first-aid advice and safety training (fast) parent programme to prevent unintentional home injuries in preschool children. Inj Prev 2012. [DOI: 10.1136/injuryprev-2012-040590d.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Cope F, Metz W, Potter B, Hartman R, Joy M, Abbruzzese B, Shuping J, Blue M, Christman L, King D. 520. Preoperative Imaging is Concordant with Intraoperative Sentinel Node Localization and a Reduction in Missed Disease When Utilizing Receptor Targeted (CD206) Tc 99m Tilmanocept in Breast Cancer and Melanoma Patients. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
34
|
Cope F, Metz W, Potter B, Hartman R, Joy M, Abbruzzese B, Shuping J, Blue M, Christman L, King D. 164. Tc 99m tilmanocept (CD206 bio-targeted) shows superiority over colloidal agents when utilized in intraoperative lymphatic mapping of breast cancer patients in two key clinical performance characteristics (patient localization and degree of localization). Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
35
|
Potter B, Brown DL. A review of studies examining the nature of selection-based and topography-based verbal behavior. Anal Verbal Behav 2012; 14:85-104. [PMID: 22477121 DOI: 10.1007/bf03392917] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Selection-based (SB) verbal behavior, in most general terms, consists of selecting stimuli from an array, which presumably has some effect on a listener. Topography-based (TB) verbal behavior consists of responses with unique topographies (e.g. speaking, signing, writing) which is also presumed to have some effect on a listener. This article reviews research examining the nature of these two types of verbal behavior. Overall, TB verbal behavior appears to be more easily acquired and may also function to mediate some SB verbal behavior.
Collapse
|
36
|
Cope F, Metz W, Abbruzzese B, Shuping J, Potter B, Blue M, Wallace A, Vera D, Agrawal A, King D. 875 Enhanced Sentinel Node Evaluation in Breast Cancer, Melanoma, and Head/neck Squamous Cell Carcinoma Via CD206 Receptor Targeting With Tc99m-tilmanocept. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71507-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Metz W, Abbruzzese B, Blackburn S, Potter B, Shuping J, Cope F, King D, Christman L. PD-0288 CORRELATION OF LYMPHOSCINTIGRAPHY W/ILM IN PIII STUDIES W/TC99M-TILMANOCEPT IN BREAST CANCER & MELANOMA. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70627-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Gelesko S, Bell R, Dierks E, Potter B. Subcranial Navigation-Assisted Repair of Frontobasal Skull Fractures. J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.joms.2011.06.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Cobb G, Dierks E, Bell R, Potter B. Poster 19: Utilization and Avoidance Patterns of Lip Splitting Mandibulotomy for Oral and Oropharyngeal Tumor Access in a Maxillofacial-Oriented Unit. J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.joms.2011.06.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Gravel J, Potter B, Dubois L. P2-102 Developmental trajectories of body mass index in childhood: is maternal smoking during pregnancy a critical exposure? Br J Soc Med 2011. [DOI: 10.1136/jech.2011.142976i.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Gravel J, Potter B, Dubois L. Parental smoking and childhood obesity: Is maternal smoking during pregnancy the critical exposure? Can J Diabetes 2011. [DOI: 10.1016/s1499-2671(11)52039-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Etchegary H, Cappelli M, Potter B, Vloet M, Graham I, Walker M, Wilson B. Attitude and knowledge about genetics and genetic testing. Public Health Genomics 2009; 13:80-8. [PMID: 19451701 DOI: 10.1159/000220034] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2008] [Accepted: 03/18/2009] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Increasing numbers of health care users may be confronted with new genetic knowledge and discoveries that offer new types of medical decision-making. How people use these new insights and make decisions about genetic risk depends, at least in part, on their knowledge and attitudes about human genetics. METHODS A postal survey administered to 560 women who had been offered prenatal screening in Ontario measured knowledge about, and attitudes toward, genetic testing and the uses of genetic information. RESULTS Respondents strongly supported the use of genetic information to improve disease diagnosis and to help understand disease causes; however, people also held a more critical attitude towards certain aspects of testing and genetic information. Relatively high levels of knowledge about genetics were also observed in this sample, although there were deficits in specific areas (e.g., transmission patterns). CONCLUSIONS Despite overall positive attitudes towards genetics, participants held more critical attitudes towards certain aspects of testing and the uses of genetic information. It would be unwise for genetics policy-makers and stakeholders to assume that a better-informed public would automatically be more supportive of all genetics research and new genetic discoveries.
Collapse
Affiliation(s)
- H Etchegary
- IWK Health Centre, Halifax, NS, B3K 6R8 Canada.
| | | | | | | | | | | | | |
Collapse
|
43
|
Little J, Potter B, Allanson J, Caulfield T, Carroll J, Wilson B. Canada: Public Health Genomics. Public Health Genomics 2008; 12:112-20. [DOI: 10.1159/000156113] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 05/30/2008] [Indexed: 11/19/2022] Open
|
44
|
Slusher BS, Rojas C, Sima A, Majer P, Tsukamoto T, Jackson PJ, Dal Canto M, Lu XM, Vomov JJ, Burak E, Rhodes C, Limsakun T, Potter B, Wozniak K. NAALADase (GCP II) inhibition as a novel therapeutic target for neuropathic pain, diabetic neuropathy, and ALS. J Neurochem 2008. [DOI: 10.1046/j.1471-4159.2002.00054.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
45
|
Wright CB, Brennan L, Brophy P, Kirsh G, Shapiro M, Potter B, Giss S, Lindeman KEW, Obial R, Fannin E. Adrenocortical tumor with left renal vein, vena cava and intrahepatic venous extension. J Cardiovasc Surg (Torino) 2008; 49:79-81. [PMID: 18212691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A 41 year old white female presented with upper respiratory distress and shortness of breath appeared on initial computed tomography (CT) scan to have a large left retroperitoneal mass with left renal vein extension including a mass up to the level of the atrium. This presentation suggested hypernephroma. She proved, however, to have an adrenal cortical carcinoma which displaced the kidney, exhibiting vascular invasion within the gland and non-adherent extension into the vena cava, atrium, common hepatic vein and left renal vein, where some adherence was present. This unusual tumor required extensive surgery for removal, including use of cardiopulmonary bypass, with good results.
Collapse
Affiliation(s)
- C B Wright
- Department of Surgery, The Jewish Hospital, Cincinnati, Ohio 45236, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Potter B. Point-of-care controls for nosocomial legionellosis. J Hosp Infect 2006; 63:232. [PMID: 16621143 DOI: 10.1016/j.jhin.2005.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2005] [Accepted: 11/15/2005] [Indexed: 10/24/2022]
|
47
|
Potter B, Giannetti N, Cecere R, Cantarovich M. Long-term calcineurin inhibitor “holiday” using daclizumab in a heart transplant patient with acute renal dysfunction. J Heart Lung Transplant 2005; 24:1126-8. [PMID: 16102455 DOI: 10.1016/j.healun.2004.10.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2004] [Revised: 09/17/2004] [Accepted: 10/11/2004] [Indexed: 11/22/2022] Open
|
48
|
Bell R, Kademani D, Dierks E, Potter B. Does site affect survival in patients with oral squamous cell carcinoma? Int J Oral Maxillofac Surg 2005. [DOI: 10.1016/s0901-5027(05)81227-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Stanway SJ, Purohit A, Woo L, Sufi S, Dobbs N, Elliott M, Potter B, Reed M, Coombes RC. First phase I trial of a steroid sulfatase inhibitor in breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. J. Stanway
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - A. Purohit
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - L. Woo
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - S. Sufi
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - N. Dobbs
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - M. Elliott
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - B. Potter
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - M. Reed
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| | - R. C. Coombes
- Imperial College London, London; Imperial College, London, United Kingdom; University of Bath, Bath, United Kingdom; Cancer Research UK, London, United Kingdom; Strathclyde Institute for Biomedical Science, Glasgow; Cancer Research UK Laboratory, Hammersmith Hosp, London, United Kingdom
| |
Collapse
|
50
|
Carmichael GR, Tang Y, Kurata G, Uno I, Streets DG, Thongboonchoo N, Woo JH, Guttikunda S, White A, Wang T, Blake DR, Atlas E, Fried A, Potter B, Avery MA, Sachse GW, Sandholm ST, Kondo Y, Talbot RW, Bandy A, Thorton D, Clarke AD. Evaluating regional emission estimates using the TRACE-P observations. ACTA ACUST UNITED AC 2003. [DOI: 10.1029/2002jd003116] [Citation(s) in RCA: 138] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- G. R. Carmichael
- Center for Global and Regional Environmental Research; University of Iowa; Iowa City Iowa USA
| | - Y. Tang
- Center for Global and Regional Environmental Research; University of Iowa; Iowa City Iowa USA
| | - G. Kurata
- Department of Ecological Engineering; Toyohashi University of Technology; Toyohashi Japan
| | - I. Uno
- Research Institute for Applied Mechanics; Kyushu University; Fukuoka Japan
| | - D. G. Streets
- Decision and Information Sciences Division; Argonne National Laboratory; Argonne Illinois USA
| | - N. Thongboonchoo
- Center for Global and Regional Environmental Research; University of Iowa; Iowa City Iowa USA
| | - J.-H. Woo
- Center for Global and Regional Environmental Research; University of Iowa; Iowa City Iowa USA
| | - S. Guttikunda
- Center for Global and Regional Environmental Research; University of Iowa; Iowa City Iowa USA
| | - A. White
- Department of Chemical Engineering; University of California, Davis; Davis California USA
| | - T. Wang
- Department of Civil and Structural Engineering; Hong Kong Polytechnic University; Hong Kong China
| | - D. R. Blake
- Department of Chemistry; University of California, Irvine; Irvine California USA
| | - E. Atlas
- National Center for Atmospheric Research; Boulder Colorado USA
| | - A. Fried
- National Center for Atmospheric Research; Boulder Colorado USA
| | - B. Potter
- University of Tulsa; Tulsa Oklahoma USA
| | - M. A. Avery
- NASA Langley Research Center; Hampton Virginia USA
| | - G. W. Sachse
- NASA Langley Research Center; Hampton Virginia USA
| | | | - Y. Kondo
- Research Center for Advanced Science and Technology; University of Tokyo; Tokyo Japan
| | - R. W. Talbot
- Institute for the Study of Earth, Oceans, and Space; University of New Hampshire; Durham New Hampshire USA
| | - A. Bandy
- Chemistry Department; Drexel University; Philadelphia Pennsylvania USA
| | - D. Thorton
- Chemistry Department; Drexel University; Philadelphia Pennsylvania USA
| | - A. D. Clarke
- School of Ocean and Earth Science and Technology; University of Hawaii; Honolulu Hawaii USA
| |
Collapse
|